Metformin use in women with polycystic ovary syndrome.
Open accessThe DOI matches its OpenAlex record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
Polycystic ovary syndrome (PCOS) is an endocrinopathy characterised by increased resistance to insulin. Metformin is one of the longest established oral insulin sensitising agents. For decades its use was restricted to management of type 2 diabetes. However, in the past two decades, its properties as an insulin sensitising agent have been explored in relation to its applicability for women with PCOS. Metformin is an effective ovulation induction agent for non-obese women with PCOS and offers some advantages over other first line treatments for anovulatory infertility such as clomiphene. For clomiphene-resistant women, metformin alone or in combination with clomiphene is an effective next step. Women with PCOS undergoing in vitro fertilisation should be offered metformin to reduce their risk of ovarian hyperstimulation syndrome. Limited evidence suggests that metformin may be a suitable alternative to the oral contraceptive pill (OCP) for treating hyperandrogenic symptoms of PCOS including hirsutism and acne. More research is required to define whether metformin has a role in improving long term health outcomes for women with PCOS, including the prevention of diabetes, cardiovascular disease and endometrial cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012512 · Cited by 19,011 · cited 1×
“Lifestyle intervention, through dietary improvement and exercise yielding weight loss, remains the cornerstone of effective long term health improvement for women with PCOS who are overweight or obese (30).”
Background(2004) · Fertility and Sterility · doi:10.1016/j.fertnstert.2003.10.004 · Cited by 9,050
Clomiphene, metformin, or both for infertility in the polycystic ovary syndrome
Legro, R. S., Barnhart, H. X., Schlaff, W. D., Carr, B. R., Diamond, M. P., Carson, S. A., Steinkampf, M. P., Coutifaris, C., McGovern, P. G., Cataldo, N. A., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa063971 · Cited by 1,027
Clark, A. M., Thornley, B., Tomlinson, L., Galletley, C., & Norman, R. J. (1998) · Human Reproduction · doi:10.1093/humrep/13.6.1502 · Cited by 789 · cited 1×
“It is clear that lifestyle intervention should be the mainstay of treatment for women with high BMI who are anovulatory in association with PCOS, a simple and healthy approach that yields a reasonable percentage of successful pregnancies without further intervention and through surprisingly modest weight reductions (1…”
BackgroundOvarian Tumors in a Cohort of Infertile Women
Rossing, M. A., Daling, J. R., Weiss, N. S., Moore, D. E., & Self, S. G. (1994) · New England Journal of Medicine · doi:10.1056/nejm199409223311204 · Cited by 721 · cited 1×
“In fact metformin carries some potential advantages over clomiphene, including no known adverse endometrial effect [whilst endometrial thinning could reduce embryo receptivity for some women using CC (20,21)], no known increase in multiple pregnancy rate (unlike that associated with CC) and thus no requirement for inc…”
BackgroundTang, T., Lord, J. M., Norman, R. J., Yasmin, E., & Balen, A. H. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003053.pub5 · Cited by 698
Palomba, S., Orio, F., Falbo, A., Manguso, F., Russo, T., Cascella, T., Tolino, A., Carmina, E., Colao, A., & Zullo, F. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-0110 · Cited by 279
Costello, M. F., Shrestha, B., Eden, J., Johnson, N., & Moran, L. J. (2007) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005552.pub2 · Cited by 197 · cited 5×
“org symptoms, compared metformin versus the combined oral contraceptive pill (OCP) (104 participants) and two RCTs compared OCP combined with metformin versus OCP alone (70 participants) (29).”
BackgroundSelf-citationSonographic determination of a possible adverse effect of clomiphene citrate on endometrial growth
Gonen, Y., & Casper, R. F. (1990) · Human Reproduction · doi:10.1093/oxfordjournals.humrep.a137165 · Cited by 193
Cited by
Metformin: Is it a drug for all reasons and diseases?
Triggle, C. R., Mohammed, I., Bshesh, K., Marei, I., Ye, K., Ding, H., MacDonald, R., Hollenberg, M. D., & Hill, M. A. (2022) · Metabolism · doi:10.1016/j.metabol.2022.155223 · Cited by 275
Linking diet to acne metabolomics, inflammation, and comedogenesis: an update
Melnik, B. (2015) · Clinical, Cosmetic and Investigational Dermatology · doi:10.2147/ccid.s69135 · Cited by 259
Epigenetic effects of metformin: from molecular mechanisms to clinical implications
Bridgeman, S. C., Ellison, G. C., Melton, P. E., Newsholme, P., & Mamotte, C. D. S. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13262 · Cited by 190
Cardiac Autonomic Neuropathy in Obesity, the Metabolic Syndrome and Prediabetes: A Narrative Review
Williams, S. M., Eleftheriadou, A., Alam, U., Cuthbertson, D. J., & Wilding, J. P. H. (2019) · Diabetes Therapy · doi:10.1007/s13300-019-00693-0 · Cited by 128
Foroozanfard, F., Jamilian, M., Jafari, Z., Khassaf, A., Hosseini, A., Khorammian, H., & Asemi, Z. (2015) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/s-0035-1548790 · Cited by 55
Metadata
- Authors
- JOHNSON, N. P.
- Venue
- PubMed
- Publisher
- National Institutes of Health
- Published
- 2014-06-01
- Volume
- 2
- Issue
- 6
- Pages
- 56-56
- OpenAlex
- W1647961127
- Cited by
- 145
- References
- 9
- FWCI
- 10.95
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Metformin use in women with polycystic ovary syndrome. https://app.cochat.ai/papers/10.3978/j.issn.2305-5839.2014.04.15
- The paper
- JOHNSON, N. P. (2014). Metformin use in women with polycystic ovary syndrome. PubMed. https://doi.org/10.3978/j.issn.2305-5839.2014.04.15
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.